CompletedPHASE2, PHASE3NCT02784171
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Canadian Cancer Trials Group
- Principal Investigator
- Quincy ChuCross Cancer Institute, Edmonton Alberta Canada
- Intervention
- Cisplatin(drug)
- Enrollment
- 520 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2024
Study locations (30)
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
- BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
- London Regional Cancer Program, London, Ontario, Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- University Health Network, Toronto, Ontario, Canada
- CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
- The Research Institute of the McGill University, Montreal, Quebec, Canada
- University Institute of Cardiology and, Québec, Quebec, Canada
- Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
- AP-HP Hopital Tenon, Paris, Cedex 20, France
- Centre Alexis Vautrin, Vandœuvre-lès-Nancy, Cedex, France
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute, Naples · Merck Sharp & Dohme LLC · Intergroupe Francophone de Cancerologie Thoracique
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02784171 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGPHASE1NCT07443020Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University